Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHAA4549A plus oseltamivir for severe influenza A
NL-OMON44177Phase 2Active, not recruiting
- Sponsor
- Genentech
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vedolizumab in Influenza A infection (3 arms), sponsored by Genentech. Primary endpoint: Time to normalization of respiratory function. Started Jan 2015; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on NL-OMON44177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44177.